Nigerians are increasingly seeking out Lenacapavir, a newly introduced injectable medication designed for the prevention of Human Immunodeficiency Virus (HIV). This surge in interest is primarily observed among individuals who are familiar with pre-exposure prophylaxis (PrEP), leading them to approach health facilities and non-governmental organizations throughout various states in Nigeria to gain access to this treatment. The increased demand for Lenacapavir comes just as the Federal Government is set to deploy this twice-yearly preventative medication in select pilot states, aligning with a broader commitment to enhance HIV prevention initiatives across the country.

The introduction of Lenacapavir marks a significant advancement in HIV prophylaxis options available to Nigerians, particularly as it provides a long-acting and convenient alternative to the daily oral PrEP medication. Developed by Gilead Sciences, this injectable treatment was recommended by the World Health Organisation in July 2025 as a new tool in the fight against HIV. Its endorsement by the WHO not only highlights the drug's efficacy but also signifies a turning point in Nigeria's public health strategy, as the government seeks to respond to the escalating interest and need for effective prevention methods.

With the impending rollout of Lenacapavir, there are potential implications for public health in Nigeria, including increased accessibility to HIV prevention tools, heightened awareness of HIV issues among the population, and possible reductions in new infections. However, the proactive engagement of health facilities and NGOs will be crucial in ensuring equitable access to this new treatment and addressing the concerns and questions of those eager to utilize Lenacapavir in their HIV prevention strategies. The situation calls for extensive outreach and education to ensure that more individuals understand their options and feel empowered to seek preventive care.